Use of platinum-based neoadjuvant chemotherapy (NACT) in patients (pts) with hormone receptor-positive breast cancer.

被引：0
|
作者：
Kyriakopoulos, Christos
Ambros, Tadeu Frantz
Montero, Alberto J.
Hurley, Judith
机构：
[1] Univ Miami, Miami, FL USA
[2] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11038
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] TISSUE PROTEOME ANALYSIS OF HORMONE RECEPTOR-POSITIVE BREAST CANCER.
    Yoneten, K. Karaosmanoglu
    Gunes, A.
    Kasap, M.
    Utkan, N. Z.
    Akpinar, G.
    Gurel, B.
    Guler, S. A.
    MOLECULAR BIOLOGY OF THE CELL, 2017, 28
  • [22] Recent time trends in chemotherapy use and oncologists' chemotherapy recommendations for early-stage, hormone receptor-positive breast cancer.
    Kurian, Allison W.
    Bondarenko, Irina
    Jagsi, Reshma
    McLeod, Chandler
    Hawley, Sarah T.
    Hamilton, Ann S.
    Ward, Kevin C.
    Katz, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Prognostic value of pathologic complete response after primary chemotherapy in patients with hormone receptor-positive breast cancer.
    Guarneri, V
    Broglio, KR
    Kau, S
    Cristofanilli, M
    Buzdar, AU
    Valero, A
    Buchholz, TA
    Meric, F
    Middleton, L
    Hortobagyi, GN
    Gonzalez-Angulo, AM
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S127 - S128
  • [24] The negative prognostic impact of downstaging after neoadjuvant chemotherapy in patients with hormone-receptor positive breast cancer.
    Takahashi, Yuko
    Hayashi, Naoki
    Matsuda, Naoko
    Kajiura, Yuka
    Yoshida, Atsushi
    Yagata, Hiroshi
    Nakamura, Seigo
    Suzuki, Koyu
    Tsunoda, Hiroko
    Yamauchi, Hideko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Neoadjuvant therapy for hormone receptor-positive breast cancer: challenges and advances
    Metzger, O.
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer
    Macaskill, E. Jane
    Renshaw, Lorna
    Dixon, J. Michael
    ONCOLOGIST, 2006, 11 (10): : 1081 - 1088
  • [27] Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer
    Hassett, Michael J.
    Hughes, Melissa E.
    Niland, Joyce C.
    Edge, Stephen B.
    Theriault, Richard L.
    Wong, Yu-Ning
    Wilson, John
    Carter, W. Bradford
    Blayney, Douglas W.
    Weeks, Jane C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5553 - 5560
  • [28] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
    Niu, Nan
    Xue, Jinqi
    Qiu, Fang
    Chen, Guanglei
    Gu, Xi
    He, Guijin
    Cao, Shuo
    Yu, Xiaopeng
    Xu, Yongqing
    Yin, Jianqiao
    Han, Sijia
    Han, Ye
    Tang, Meiyue
    Zhao, Yafei
    Zheng, Ran
    Zheng, Xinyu
    Xu, Hong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients
    Boland, Michael R.
    Ryan, Eanna J.
    Nugent, Timothy
    Gilroy, Darina
    Kelly, Michael E.
    Kennedy, John
    Maguire, Aoife
    Alazawi, Dhafir
    Boyle, Terence J.
    Connolly, Elizabeth M.
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 122 (05) : 861 - 868
  • [30] Conversion to node-negative after neoadjuvant chemotherapy is a surrogate prognostic marker in patients with hormone receptor-positive breast cancer
    Takahashi, Y.
    Hayashi, N.
    Matsuda, N.
    Kajiura, Y.
    Yoshida, A.
    Yagata, H.
    Nakamura, S.
    Suzuki, K.
    Tsunoda, H.
    Yamauchi, H.
    CANCER RESEARCH, 2013, 73
12345